Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
51 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2016, provides an overview of the Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline landscape. Shigella Infections (Shigellosis) is an intestinal disease caused by bacteria known as shigella. Symptoms include diarrhea, abdominal cramps and fever. Predisposing factors include eating contaminated food, age, international travelers and homosexual men. Treatment includes antibiotics. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacillary Dysentery (Shigellosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 4 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 3 and 1 molecules, respectively for Bacillary Dysentery (Shigellosis). Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Bacillary Dysentery (Shigellosis) (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Bacillary Dysentery (Shigellosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Bacillary Dysentery (Shigellosis) (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Bacillary Dysentery (Shigellosis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Bacillary Dysentery (Shigellosis) (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Bacillary Dysentery (Shigellosis) (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Bacillary Dysentery (Shigellosis) Overview 7 Therapeutics Development 8 Pipeline Products for Bacillary Dysentery (Shigellosis) - Overview 8 Pipeline Products for Bacillary Dysentery (Shigellosis) - Comparative Analysis 9 Bacillary Dysentery (Shigellosis) - Therapeutics under Development by Companies 10 Bacillary Dysentery (Shigellosis) - Therapeutics under Investigation by Universities/Institutes 11 Bacillary Dysentery (Shigellosis) - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Bacillary Dysentery (Shigellosis) - Products under Development by Companies 14 Bacillary Dysentery (Shigellosis) - Products under Investigation by Universities/Institutes 15 Bacillary Dysentery (Shigellosis) - Companies Involved in Therapeutics Development 16 Akthelia Pharmaceuticals Limited 16 GlaxoSmithKline Plc 17 Microbiotix, Inc. 18 Protein Potential, LLC 19 Visterra, Inc. 20 Bacillary Dysentery (Shigellosis) - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Combination Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 (shigella + typhoid) vaccine - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 AKT-10081 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 GVXNSD-133 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 INX-201 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 KKL-35 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 SC-599 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 SE-1 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 SF2a-TT15 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 shigella vaccine - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 shigella vaccine - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 shigella vaccine - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 shigella vaccine 1 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Shigetec - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 VIS-GMN - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Bacillary Dysentery (Shigellosis) - Dormant Projects 45 Bacillary Dysentery (Shigellosis) - Discontinued Products 46 Bacillary Dysentery (Shigellosis) - Product Development Milestones 47 Featured News & Press Releases 47 Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine 47 Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates 47 Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease 48 Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine 49 Appendix 50 Methodology 50 Coverage 50 Secondary Research 50 Primary Research 50 Expert Panel Validation 50 Contact Us 50 Disclaimer 51
List of Tables
Number of Products under Development for Bacillary Dysentery (Shigellosis), H2 2016 8 Number of Products under Development for Bacillary Dysentery (Shigellosis) - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Bacillary Dysentery (Shigellosis) - Pipeline by Akthelia Pharmaceuticals Limited, H2 2016 16 Bacillary Dysentery (Shigellosis) - Pipeline by GlaxoSmithKline Plc, H2 2016 17 Bacillary Dysentery (Shigellosis) - Pipeline by Microbiotix, Inc., H2 2016 18 Bacillary Dysentery (Shigellosis) - Pipeline by Protein Potential, LLC, H2 2016 19 Bacillary Dysentery (Shigellosis) - Pipeline by Visterra, Inc., H2 2016 20 Assessment by Monotherapy Products, H2 2016 21 Assessment by Combination Products, H2 2016 22 Number of Products by Stage and Target, H2 2016 24 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Bacillary Dysentery (Shigellosis) - Dormant Projects, H2 2016 45 Bacillary Dysentery (Shigellosis) - Discontinued Products, H2 2016 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.